<code id='7F7673C832'></code><style id='7F7673C832'></style>
    • <acronym id='7F7673C832'></acronym>
      <center id='7F7673C832'><center id='7F7673C832'><tfoot id='7F7673C832'></tfoot></center><abbr id='7F7673C832'><dir id='7F7673C832'><tfoot id='7F7673C832'></tfoot><noframes id='7F7673C832'>

    • <optgroup id='7F7673C832'><strike id='7F7673C832'><sup id='7F7673C832'></sup></strike><code id='7F7673C832'></code></optgroup>
        1. <b id='7F7673C832'><label id='7F7673C832'><select id='7F7673C832'><dt id='7F7673C832'><span id='7F7673C832'></span></dt></select></label></b><u id='7F7673C832'></u>
          <i id='7F7673C832'><strike id='7F7673C832'><tt id='7F7673C832'><pre id='7F7673C832'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:entertainment    Page View:72
          Rising drug prices —Medicare coverage from STAT
          Medicare on Friday released new details about how its new drug price negotiation program will work, just two months before it’s set to start. APStock

          WASHINGTON — Medicare on Friday released new details about how its new drug price negotiation program will work, just two months before it’s set to start.

          Medicare released an initial outline of how the program will work in March. Some parts, including the outline of how drugs would be selected for the negotiation process, were immediately final. The agency asked drug companies, patients, and other affected parties to weigh in on other parts about how the process would proceed, what factors would be considered, and how drugmakers would be held accountable.

          advertisement

          Newsletters

          Sign up for D.C. Diagnosis

          An insider's guide to the politics and policies of health care

          Please enter a valid email address. Privacy Policy

          The negotiation process was created last August in Democrats’ drug pricing reform law, and Medicare is supposed to select the first 10 drugs that will be subject to negotiation by Sept. 1.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Roche to buy Carmot Therapeutics, developer of obesity drugs
          Roche to buy Carmot Therapeutics, developer of obesity drugs

          SebastienBozon/AFPviaGettyImagesLONDON—Theboomingobesitymarketisattractinganotherplayer,aspharmagian

          read more
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more

          ARCH Venture Partners tops STAT's 2023 biotech VC rankings

          AdobeThisarticleisadaptedfromthe2023editionofSTAT’sannualreport,“Rankingbiotech’stopventurecapitalfi